Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population

Clinical Chemistry

Volumn 57, Issue 3, 2011, Pages 490-501

  Van Deventer, Hendrick E ^a   Miller, W Greg ^b   Myers, Gary L ^c   Sakurabayashi, Ikunosuke ^d   Bachmann, Lorin M ^b   Caudill, Samuel P ^c   Dziekonski, Andrzej ^b   Edwards, Selvin ^c   Kimberly, Mary M ^c   Korzun, William J ^b   Leary, Elizabeth T ^e   Nakajima, Katsuyuki ^f   Nakamura, Masakazu ^g   Shamburek, Robert D ^a   Vetrovec, George W ^b   Warnick, G Russell ^h   Remaley, Alan T ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e Pac Biometrics Research Foundation   (United States)

^f Otsuka Pharmaceutical   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h Health Diagnostics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REAGENT; TRIACYLGLYCEROL;

ACCURACY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLASSIFICATION; CONTROLLED STUDY; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MEASUREMENT; SCORING SYSTEM;

BLOOD CHEMICAL ANALYSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DATA INTERPRETATION, STATISTICAL; DYSLIPIDEMIAS; FASTING; HUMANS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES; ULTRACENTRIFUGATION;

EID: 79952223409     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.154773     Document Type: Article

References (37)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
2. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002;48:236-54.
3. Nauck M, Wiebe D, Warnick GR. Measurement of high-density-lipoprotein cholesterol. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing. 2nd ed. Washington, DC: AACC Press; 2000:227-30.
4. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981;141:1128-31.
5. Castelli WP, Doyle JT, Gordon T, Hames CG, Hjortland MC, Hulley SB, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1977;55:767-72.
6. Myers GL, Kimberly MM, Waymack PP, Smith SJ, Cooper GR, Sampson EJ. A reference method laboratory network for cholesterol: a model for standardization and improvement of clinical laboratory measurements. Clin Chem 2000;46:1762-72.
7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
8. Schectman G, Patsches M, Sasse EA. Variability in cholesterol measurements: comparison of calculated and direct LDL cholesterol determinations. Clin Chem 1996;42:732-7. (Pubitemid 26142092)
9. Miller WG, Myers GL, Sakurabayashi I, Bachman LM, Caudill SP, Dziekonski A, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010;56:977-86.
10. Sahu S, Chawla R, Uppal B. Comparison of two methods of estimation of low density lipoprotein cholesterol, the direct versus Friedewald estimation. Indian J Clin Biochem 2005;20:54-61. (Pubitemid 41215704)
11. Miller WG, Waymack PP, Anderson FP, Ethridge SF, Jayne EC. Performance of four homogeneous direct methods for LDL-cholesterol. Clin Chem 2002;48:489-98. (Pubitemid 34174579)
12. Warnick GR, Kimberly MM, Waymack PP, Leary ET, Myers GL. Standardization of measurements for cholesterol, triglycerides, and major lipoproteins. Lab Med 2008;39:481-90.
13. Lachenbruch PA, Lynch CJ. Assessing screening tests: extensions of McNemar's test. Stat Med 1998;17:2207-17. (Pubitemid 28466819)
14. Ricos C, Alvarez V, Cava F, Garcia-Lario J, Hernandez A, Jimenez CM, J, et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999;59:491-500. (Pubitemid 30056739)
15. Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clin Chem 1988;34:2456-9. (Pubitemid 19017248)
16. Rifai N, Merrill JR, Holly RG. Postprandial effect of a high fat meal on plasma lipid, lipoprotein cholesterol and apolipoprotein measurements. Ann Clin Biochem 1990;27(Pt 5):489-93.
17. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001.
18. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009;55:888-94.
19. Yu HH, Ginsburg GS, Harris N, Rifai N. Evaluation and clinical application of a direct low-density lipoprotein cholesterol assay in normolipidemic and hyperlipidemic adults. Am J Cardiol 1997;80:1295-9. (Pubitemid 27513328)
20. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988;29:469-79.
21. Lund SS, Petersen M, Frandsen M, Smidt UM, Parving HH, Vaag AA, Jensen T. Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus. Scand J Clin Lab Invest 2008;68:628-40.
22. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care 2005;28:1916-21. (Pubitemid 41060963)
23. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003;26:16-23. (Pubitemid 36928989)
24. Jiang R, Schulze MB, Li T, Rifai N, Stampfer MJ, Rimm EB, Hu FB. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care 2004;27:1991-7. (Pubitemid 38989244)
25. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776-85. (Pubitemid 47263160)
26. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294:326-33. (Pubitemid 41043776)
27. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002;106:2537-42. (Pubitemid 35340688)
28. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-9. (Pubitemid 32681162)
29. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008;101:1003-8.
30. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006;98:1363-8. (Pubitemid 44666646)
31. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
32. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-22.
33. Kukita H, Hiwada K, Kokubu T. Serum apolipoprotein A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease. Atherosclerosis 1984;51:261-7.
34. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJ. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983;309:385-9. (Pubitemid 13033962)
35. van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146:640-8. (Pubitemid 351650519)
36. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290:932-40. (Pubitemid 37430466)
37. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004;109(23 Suppl 1):III2-7.